Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Pirtenidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | HTT | P42858 | 6/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | GALR3 | O60755 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octenidine SCHEMBL20597431 | 1.00 | NPC1 (0.59) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL11469011 | 1.00 | NPC1 (0.59) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL10570053 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL20764598 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL10569601 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL23393769 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| Pirtenidine SCHEMBL2108103 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL124821 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL126751 | 0.97 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Hydrochloric Acid SCHEMBL10573899 | 0.97 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4598082-A | DENTISTRY | STERLING DRUG INC. (US) | 1986-07-01 | — | — | US | claimed |
| US-11014907-B2 | Octendidine based compounds | DISHMAN CARBOGEN AMCIS LTD. (IN) | 2021-05-25 | — | — | US | disclosed |
| US-20200377471-A1 | OCTENDIDINE BASED COMPOUNDS | DISHMAN CARBOGEN AMCIS LTD. (IN) | 2020-12-03 | — | — | US | disclosed |
| EP-3672942-A1 | OCTENIDINE BASED COMPOUNDS | Dishman Carbogen Amcis Ltd. (IN) | 2020-07-01 | — | — | EP | disclosed |
| CN-111051285-A | Octenidine-based compounds | 迪氏曼卡博金艾美斯有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019038669-A1 | OCTENIDINE BASED COMPOUNDS | DISHMAN CARBOGEN AMCIS LTD. (IN) | 2019-02-28 | — | — | WO | disclosed |
| EP-0174632-B1 | ANTI-MICROBIAL N-(1-(ALKYL OR ARYLMETHYL)-4(1H)-PYRIDINYLIDINE)ALKANAMINES AND ACID ADDITION SALTS THEREOF AND PROCESS FOR PREPARATION, METHODS OF USE AND COMPOSITIONS THEREOF | STERLING DRUG INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| US-4839372-A | ANTIPLAQUE AGENTS | STERLING DRUG INC. (US) | 1989-06-13 | — | — | US | disclosed |
| US-4598082-A | DENTISTRY | STERLING DRUG INC. (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0174632-A1 | Anti-microbial N-(1-(alkyl or arylmethyl)-4(1H)-pyridinylidine)alkanamines and acid addition salts thereof and process for preparation, methods of use and compositions thereof | STERLING DRUG INC. (US) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377471-A1 | OCTENDIDINE BASED COMPOUNDS | SSTR5, SSTR4, SSTR3 | NPC1 1145/4885RAB9A 1905/4885HTT 493/4885 |
| US-11014907-B2 | Octendidine based compounds | SSTR5, SSTR4, SSTR3 | NPC1 1145/4885RAB9A 1905/4885HTT 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.